

## AMENDMENTS TO THE CLAIMS

Please amend claims 15 and 26 and cancel claim 18, as shown below. A complete listing of the claims, including their current status, is provided below:

1-14 (cancelled)

15. (Currently amended) A method for inhibiting an immune reaction, said method comprising administering a peptide comprising the amino acid sequence of:

i) Gly-Ala-His-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Arg (SEQ ID NO:1) or a conservative amino acid substitution thereof at a residue position other than 4, 5, 6, 9, 10 or 11;

ii) Gly-Ala-Ala-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Arg (SEQ ID NO:7) or a conservative amino acid substitution thereof at a residue position other than 4,5, 6, 9, 10 or 11;

iii) Gly-Ala-His-Trp-Gln-Phe-Ala-Ala-Leu-Thr-Val-Arg (SEQ ID NO:8) or a conservative amino acid substitution thereof at a residue position other than 4,5, 6, 9, 10 or 11; and

iv) Gly-Ala-His-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Ala (SEQ ID NO:9) or a conservative amino acid substitution thereof at a residue position other than 4,5, 6, 9, 10 or 11,

wherein the peptide which selectively binds hyaluronic acid and wherein said administering inhibits an immune reaction..

16. (Original) The method of claim 15, wherein the immune reaction is cutaneous.

17. (Original) The method of claim 15, wherein the peptide inhibits leukocyte infiltration.

18-25 (cancelled)

Attorney Docket No. SWMC-001DIV

26. (currently amended) The method of claim 15, wherein said method comprises administering:

a carrier material; and

a said peptide the amino acid sequence of:

i) —— Gly-Ala-His-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Arg or a conservative amino acid substitution thereof;

ii) —— Gly-Ala-Ala-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Arg or a conservative amino acid substitution thereof;

iii) —— Gly-Ala-His-Trp-Gln-Phe-Ala-Ala-Leu-Thr-Val-Arg or a conservative amino acid substitution thereof; or

iv) —— Gly-Ala-His-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Ala or a conservative amino acid substitution thereof;

to a subject with an immune reaction.